



• **Name:** Ju-Won Roh, MD, PhD

• **Current Position:**

Professor, Chair, Department of Obstetrics & Gynecology, Dongguk University Ilsan Hospital

• **Country:** Korea

• **Educational Background:**

1988.3-1990.2 Seoul National University, Seoul, Korea
1990.3-1994.2 M.D., College of Medicine, Seoul National University, Korea
1999.3-2003.2 Doctor of Medical Science, Graduate School of University, Seoul National University, Korea

• **Professional Experiences:**

1999.3-2001.2 Fellowship in Dept of Ob/Gyn, Seoul National University Hospital
2001.3-2004.8 Chief Researcher, Uterine Cancer Branch, National Cancer Center, Korea
2001.7-2001.8 Visiting Doctor, Friedrich-Schiller University, Jena, Germany
2001.7-2001.8 Visiting Doctor, Leipzig University, Leipzig, Germany
2004.9-2009.8 Assistant Professor in Dept of OB/Gyn, Dongguk University Ilsan Hospital, Korea
2009.9-2014.2 Associate Professor in Dept of OB/Gyn, Dongguk University Ilsan Hospital, Korea
2009.12-2011.2 Visiting Associate Professor, Dept of Gynecol Oncol, MD Anderson Cancer Center, Texas, USA
2011.3-present Chair, in Dept of OB/Gyn, Dongguk University Ilsan Hospital, Korea
2014.3-present Professor (tenure) in Dept of OB/Gyn, Dongguk University Ilsan Hospital, Korea

• **Professional Organizations**

1999. 3- present The Korean Society of Obstetrics and Gynecology Active Member
2000. 6 - present The Korean Cancer Association Active Member
2000.11- present The Korean Society of Psychosomatic Obstetrics and Gynecology. Active Member

| | | |
|-------------------|--|---|
| 2000. 6 - present | The Korean Society of Gynecologic Oncology | Active Member |
| 2002. 3 - present | The Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery | Active Member |
| 2004. 3- present | The Korean Society of Biochemistry and Molecular Biology | Active Member |
| 2004. 6 - present | The Korean Society of Urogynecology | Active Member |
| 2007.3~2008.2 | Insurance Committee of the Korean Society of Obstetrics & Gynecology | Member of Insurance committee |
| 2007.3~ 2013.2 | The Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery | Editorial Board |
| 2013.3~ present | The Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery | Academician |
| 2012.7~2014.06 | The Korean Cancer Association | Member of Publication Committee |
| 2014.03~2016.2 | The Korean Society of Psychosomatic Obstetrics and Gynecology. | Academician |
| 2015.3 ~ present | Journal of Gynecologic Oncology | Editorial Board |
| 2016.02~ present | The Korean Society of Psychosomatic Obstetrics and Gynecology. | Chairman of International Cooperation Committee |

•Awards


| | |
|---------------|--|
| June 9, 2000 | The 2nd SB Award (in 26th Annual Congress of Korean Cancer Association) |
| June 8, 2001 | The 3rd GSK Award (in 27th Annual Congress of Korean Cancer Association) |
| June 12, 2009 | The 11th GSK Award (in 35th Annual Congress of Korean Cancer Association) |
| June 17, 2012 | Merit Award (in 10th International Conference of Asian Clinical Oncology Society) |
| June 14, 2013 | The 15th GSK Award (in 39th Annual Congress of Korean Cancer Association) |
| June 19, 2015 | Novartis Merit Award (in 41st Annual Congress of Korean Cancer Association and International Cancer Conference) |



- **Main Scientific Publications:** International (SCI) : 41, Domestic : 56

- Kim JW, Roh JW, Park NH, Song YS, Kang SB, Lee HP. Polymorphism of p53 codon 72 and the risk of cervical cancer in Korean women. *Am J Obstet Gynecol* 2001;184:55-8.(IF 4.681)
- Roh JW, Kim JW, Kim MH, Park NH, Song YS, Kang SB, Lee HP. Polymorphism in Codon 31 of p21 and Cervical Cancer Susceptibility in Korean women. *Cancer Lett* 2001;165:59-62.(IF 5.992)
- Roh JW, Kim MH, Seo SS, Kim SH, Kim JW, Park NH, Song YS, Park SY, Kang SB, Lee HP. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. *Cancer Lett* 2002;184:57-63. (IF 5.992)
- Kim JW, Roh JW, Park NH, Song YS, Kang SB, Lee HP. Interferon, alpha 17 (IFNA17) Ile 184Arg polymorphism and cervical cancer risk. *Cancer Lett* 2003;189:183-8. (IF 5.992)
- Lee SA, Kim JW, Roh JW, Choi JY, Lee KM, Yoo KY, Song YS, Kang DH. Genetic polymorphism of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women. *GynecolOncol*2004;93:14-18.(IF 4.198)
- Roh JW, Kim JW, Park NH, Song YS, Park IA, Park SY, Kang SB, Lee HP. p53 and p21 genetic polymorphism and susceptibility to endometrial cancer. *Gynecol Oncol* 2004;93:499-505. (IF 4.198)
- Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, Kong HJ, Rha SH, Jung SI, Kim JI, Jung KY, van Doorn LJ, Quint W. Prevalence and Determinants of Genital Infection with Papillomavirus, in Female and Male University. *J Infect Dis* 2004;190:468-76.(IF 6.344)
- Chung HH, Lee S, Sim JS, Kim JY, Seo SS, Park SY, Roh JW. Pretreatment laparoscopic surgical staging in locally advanced cervical cancer: Preliminary results in Korea. *Gynecol Oncol* 2005;97(2):468-475. (IF 4.198)
- Kim SK, Kang KW, Roh JW, Sim JS, Lee ES, Park SY. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. *Eur J Nucl Med Mol I* 2005;32:757-763.(IF 5.537)
- Roh JW, Seo SS, Lee S, Kang KW, Kim SK, Sim JS, Kim JY, Hong EK, Cho DS, Lee JS, Park SY. Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: A prospective surgicopathologic correlation study. *Eur J Cancer* 2005;41(14):2086-92. (IF 6.163)

- Choi HJ, Roh JW, Seo SS, Lee S, Kim JY, Kim SK, Kang KW, Lee JS, Jeong JY, Park SY. Comparison of accuracies of MRI and PET/CT in presurgical detection of lymph node metastases in patients with uterine cervical cancer: a prospective study. *Cancer* 2006;106(4):914-22.(IF 5.649)
- Kim JW, Shin HJ, Kim TH, Cho KH, Shin KH, Kim BK, Roh JW, Lee S, Park SY, Hwang YJ, Han IO. Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. *J Cancer Res Clin Oncol* 2006;132(5):302-8.(IF 3.141)
- Lee S, Shin HJ, Han IO, Hong EK, Park SY, Roh JW, Shin KH, Kim TH, Kim JY. Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer. *Cancer Sci* 2007;98:329-333.(IF 3.896)
- Lee KY, Jun HA, Roh JW, Song JE. Successful twin pregnancy after vaginal radical trachelectomy using transabdominal cervicoisthmic cerclage. *Am J Obstet Gynecol* 2007;197(3):e5-6 (IF 4.681)
- Kim JY, Park S, Nam BH, Roh JW, Lee CH, Kim YH, Shin HJ, Lee SK, Kong SY, Seong MW, Han TJ, Lee MY, Cho KH, Park SY. Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. *J Clin Oncol* 2009Oct20;27(30):5088-93(IF 20.982).
- Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma. *Clin Cancer Res*; 2010;16(9) May: 2562–70. (IF 8.738).
- Roh JW, Kim BK, Lee CH, Kim J, Chung HH, Kim JW, Park NH, Song YS, Park SY, Kang SB.p53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. *Oncol Res*2010;18(9):453-9.(IF 3.957)
- Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles. *Clin Cancer Res* 2010;16(15):3910-22. (IF 8.738)
- Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK. Functional roles of Src and Fgr in ovarian carcinoma. *Clin Cancer Res* . 2011 Apr 1;17(7):1713-1721. (IF 8.738)
- Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV,



- Thanappapasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee JS, Ellis LM, Lopez-Berestein G, McConathy WJ, Prokai L, Lacko AG, Sood AK. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. *Neoplasia* 2011 Apr; 13(4):309-19. (IF 4.509)
- Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK. Targeting Src in Mucinous Ovarian Carcinoma. *Clin Cancer Res.* 2011; 17 (16):5367-78. (IF 8.738)
 - Hu W, Lu C, Han HD, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora EM, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman R, Sood AK. Biological roles of the Delta family notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. *Cancer Res.* 2011; 71:6030-6039. (IF 8.556)
 - Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, Sood AK. A novel platform for detection of CK+ and CK- CTCs. *Cancer Discovery* 2011; 1(7):580-586. (IF: 19.783)
 - Hussein YR, Sood AK, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z, Roh JW, Han HD, Lopez-Berestein G, Ali-Fehmi R. Clinical and biological relevance of enhancer of zeste homolog 2 in triple negative breast cancer. *Human Pathol* 2012; 43(10):1638-44. (IF: 2.791)
 - Zhou J, Roh JW, Bandyopadhyay S, Chen Z, Munkarah A, Hussein Y, Alesh B, Jazaerly T, Hayek K, Sood AK, Ali-Fehmi R. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. *Gynecol Oncol* 2013 Feb; 128(2); 344-8. (IF 4.198)
 - M Moreno-Smith, SJ Lee, C Lu, AS Nagaraja, G He, R Rupaimoole, HD Han, NB Jennings, **JW Roh**, M Nishimura, Y Kang, JK Allen, GN Armaiz, K Matsuo, MM Shahzad, J Bottsford-Miller, RR Langley, SW Cole, SK Lutgendorf, ZH Siddik, AK Sood. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. *Neoplasia* .2013 May; 15(5):502-10. (IF 4.509)
 - Matsuo K, Nishimura M, Komurov K, Shahzad MMK, Ali-Fehmi R, **Roh JW**, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood



AK. Platelet-derived growth factor receptor alpha (PDGFR α) targeting and relevant biomarkers in ovarian carcinoma. *Gynecol Oncol* 2014;Jan;132(1):166-75. (IF 4.198)

- J Huang, W Hu, J Bottsford-Miller, T Liu, HD Han, B Zand, S Pradeep, **JW Roh**, D Thanappapa, HJ Dalton, CV Pecot, R Rupaimoole, C Lu, B Fellman, D Urbauer, Y Kang, NB Jennings, L Huang, MT Deavers, R Broaddus, RL Coleman, AK Sood. Crosstalk between EphA2 and Braf/Craf is a key determinant of response to Dasatinib. *Clin Cancer Res* 2014 Apr 1;20(7):1846-55. (IF 8.738)
- **JW Roh**, J Huang, W Hu, XY Yang, NB Jennings, V Sehgal, BH Sohn, HD Han, SJ Lee, D Thanappapasr, J Bottsford-Miller, B Zand, HJ Dalton, RA Previs, AN Davis, K Matsuo, JS Lee, P Ram, RL Coleman, AK Sood. Biological effects of platelet-derived growth factor receptor α blockade in uterine cancer. *Clin Cancer Res* 2014;May 15;20(10): 2740-50. (IF 8.738)
- **Roh JW**, Lee DO, Suh DH, Lim MC, Seo SS, Chung J, Lee S, Park SY. Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial. *J Gynecol Oncol*, 2015;26(2) :90-99 (IF 2.522)